Kidswell Bio (4584) · InitiativeRestated
Joint Development of an Aflibercept Biosimilar with 癸巳化成
First written in FY2020-Q3. 1 of 2 entries say "Restated". Latest entry: FY2020.
2entries
1years
0from disclosures
How it moved
Same theme, other companies
Joint Development and Commercialization of BiosimilarsA theme 2 companies write about · 0 as a headwind · 6 as a tailwind
0 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2020RestatedAnnual report
「In December of the same year, the Company entered into a joint development agreement with Kishi Kasei Co., Ltd. concerning an aflibercept follow-on biologic and commenced development.」
The Company has reconfirmed the joint development of an aflibercept follow-on biologic with Kishi Kasei as a development project already under way. - FY2020-Q3First statedAnnual report
「In December of the same year, the Company entered into a joint development agreement with Kishi Kasei Co., Ltd. concerning an aflibercept biosimilar and commenced development.」
To expand its biosimilars business, the Company entered into a joint development agreement with Kishi Kasei for an aflibercept biosimilar and commenced development.